Post-term Pregnancy: Epidemiology, Outcomes, and Management

2020 ◽  
Author(s):  
Aaron B Caughey

The term pregnancy ranges from 37 and 0/7 weeks’ gestation to 41 6/7 weeks’ gestation; a pregnancy that progresses to 42 weeks and beyond is deemed a postterm pregnancy. Such pregnancies are uncommon, in well dated pregnancies, likely less than 3-5 percent. However, because of induction of labor, in the United States it is less than 1%. Postterm pregnancy is associated with a number of complications including stillbirth, meconium, both fetal growth restriction and fetal macrosomia, birth injury, preeclampsia, cesarean delivery, operative vaginal delivery, chorioamnionitis, and postpartum hemorrhage. One of the primary reasons for induction of labor prior to 42 weeks is that it has been associated with a lower risk of many of these complications including cesarean delivery. In women who do not wish to undergo induction of labor, antenatal testing is indicated certainly by 41 weeks of gestation and is commonly used at earlier gestations.  This review contains 1 table, 2 figures and 83 references Key words: cesarean, induction, late term, acrosomia, meconium, postterm, stillbirth, term

Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 1367-P
Author(s):  
JENNIFER GRASCH ◽  
KATHERINE MILLER ◽  
DAVID HAAS ◽  
METHODIUS TUULI ◽  
CHRISTINA M. SCIFRES

2021 ◽  
Vol 76 (8) ◽  
pp. 455-456
Author(s):  
Rie Sakai-Bizmark ◽  
Michael G. Ross ◽  
Dennys Estevez ◽  
Lauren E. M. Bedel ◽  
Emily H. Marr ◽  
...  

2022 ◽  
Vol 226 (1) ◽  
pp. S481
Author(s):  
Ariane C. Youssefzadeh ◽  
Rauvynne N. Sangara ◽  
Rachel S. Mandelbaum ◽  
Kazuhide Matsushima ◽  
Maximilian Klar ◽  
...  

2007 ◽  
Vol 22 (1) ◽  
pp. 5-11 ◽  
Author(s):  
Cynthia L. Ogden ◽  
Kenneth C. Schoendorf ◽  
John L. Kiely ◽  
Matthew W. Gillman

2020 ◽  
Vol 10 (4) ◽  
pp. 204589402091183
Author(s):  
John W. McConnell ◽  
Yuen Tsang ◽  
Janis Pruett ◽  
William Drake III

Two oral medications targeting the prostacyclin pathway are available to treat pulmonary arterial hypertension in the United States: oral treprostinil and selexipag. We compared real-world hospitalization in patients receiving these medications. A retrospective administrative claims study was conducted using the Optum® Clinformatics® Data Mart database. Patients with pulmonary hypertension were identified using diagnostic codes. Cohort inclusion required age ≥ 18 years, first oral treprostinil or selexipag prescription between 1 January 2015 and 30 September 2017 (index date), and continuous enrollment in the prior ≥6 months. Patients who switched index drug were excluded. Follow-up was from index date until the first of end of index drug exposure, end of continuous enrollment, death, or 31 December 2017. Multivariable Cox proportional hazard and Poisson regression were used to compare risk and rate, respectively, of hospitalization associated with oral treprostinil vs. selexipag, adjusting for potential confounders. The study cohort included 99 patients receiving oral treprostinil and 123 receiving selexipag. Mean age was 61 years, and most patients were females (71%). Compared with oral treprostinil, selexipag was associated with a 46% lower risk of all-cause hospitalization (hazard ratio 0.54, 95% confidence interval 0.31, 0.92; P = 0.02), a 47% lower risk of pulmonary hypertension-related hospitalization (hazard ratio 0.53, 95% confidence interval 0.31, 0.93; P = 0.03), a 42% lower all-cause hospitalization rate (rate ratio 0.58, 95% confidence interval 0.39, 0.87; P = 0.01), and a 46% lower pulmonary hypertension-related hospitalization rate (rate ratio 0.54, 95% confidence interval 0.35, 0.82; P = 0.004). This study suggests that selexipag is associated with lower hospitalization risk and rate than oral treprostinil.


2020 ◽  
Vol 2 (1) ◽  
pp. 100071
Author(s):  
Manal S. Sheikh ◽  
Gregg Nelson ◽  
Stephen L. Wood ◽  
Amy Metcalfe

1992 ◽  
Vol 326 (24) ◽  
pp. 1587-1592 ◽  
Author(s):  
Mary E. Hannah ◽  
Walter J. Hannah ◽  
Jonathan Hellmann ◽  
Sheila Hewson ◽  
Ruth Milner ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document